Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma
Part of paid clinical trials in Kansas City, Kansas.
- Sponsor
- University of Kansas Medical Center
- Study ID
- NCT06985225
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Hyperpolarized 129 Xenon — COMBINATION_PRODUCTXenon gas contrast agent for MRI
Study Details
In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with severe asthma. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.
Key Dates
- Start date
- Jun 1, 2025
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 5 participants (estimated)
Arms
- Arm: Main GroupPatients with Severe Asthma with a high T2 phenotype
Primary Outcome Measure
Ventilation Defect in Mucus blocked Regions [ Time Frame: 12-weeks ]
Central Contacts
- Cristal Monge(913) 945-9399
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | Peter Niedbalski, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Kansas City, KS
By condition
By specialty
By research site
Related Studies
- Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe AsthmaRecruiting · Bastiaan Driehuys · Durham, North Carolina
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)PHASE3 · Recruiting · Generate Biomedicines · Northridge, California
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)PHASE3 · Recruiting · Generate Biomedicines · Bakersfield, California
- A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe AsthmaPHASE2 · Not Yet Recruiting · Kinaset Therapeutics Inc · Lancaster, California